Original Research Article

<https://doi.org/10.20546/ijcmas.2018.710.018>

Effects of Antibiotic Withdrawal on Multidrug Resistant *Escherichia coli*

Hitesh Kumar* and Sunil Maherchandani

Department of veterinary Microbiology, CVAS, Bikaner (Raj.), India

*Corresponding author

ABSTRACT

Antimicrobial resistance (AMR) is an increasingly serious threat to global public health. The increase in antibiotic consumption is well evident which accelerates the AMR. The continuous dissemination of 'multidrug-resistant' (MDR) bacteria drastically reduces the efficacy of antibiotics and consequently increases the frequency of therapeutic failure. In MDR bacteria the over-expression of efflux pumps that expels antibiotics which contribute to the increased resistance by decreasing the intracellular concentration of antibiotics. In the present study 42 MDR isolates from different groups (human, pig, and poultry) were evaluated for their antibiogram profile, mechanism of antibiotic resistance prevalent in them and to know the effects of withdrawal of antibiotics on bacterial resistance MDR bacteria were sub-culture. Withdrawal of antibiotic definitely helps in reverting the resistant phenotype in majority of the MDRs. The recent investigation on the AMR, including adaptive mechanism to resistance for various antibiotics, may pave the way towards the decreased frequency of emergence of *Escherichia coli* strains that are highly resistant.

Keywords

Multidrug-resistance,
Efflux activity, Efflux
pumps, Antibiotic
withdrawal

Article Info

Accepted:
04 September 2018
Available Online:
10 October 2018

Introduction

Antibiotic resistance mechanisms reported in Gram-negative bacteria are causing a worldwide health problem. AMR develops when a microorganism no longer responds to a drug to which it was originally sensitive. This AMR occurs naturally over time. However, the misuse and overuse of antimicrobials accelerates this process. The increase in antibiotic consumption is well evident from the fact that there has been an increase of antibiotic usage by 30% globally between 2000 and 2010 (Van Boeckel *et al.*, 2014). In India itself a 40 % increase in the use of antibiotics has been reported in a survey from

2005 to 2009 (Ganguly *et al.*, 2011). The burden of increased antibiotic use is reflected in the fact that infectious disease mortality rate in India currently is 416.75 per 100,000 persons (Laxminarayan and Chaudhury, 2016).

Reductions in antimicrobials use have been reported to achieve decrease in antimicrobial resistance (Barbosa and Levy, 2000; Nys *et al.*, 2005).

AMR being a global burden of complex epidemiology, an integrated One Health approach is required to control this problem. One Health approach recognizes that the

health of people is connected to the health of animals and the environment and AMR has clear links to each of these three domains. Resistant organisms exist in humans, animals, food and the environment and antibiotic resistant bacteria can be transmitted between the three domains (Robinson *et al.*, 2016).

Antibiotic resistance in microbes can either be inherited/acquired or non-inherited/adaptive. Acquired antibiotic resistance is generally associated with extrachromosomal elements, like plasmids, transposons and integrons carrying antibiotic resistance genes, transferred from one bacteria to another through horizontal gene transfer or vertically from one generation of bacteria to the next (Courvalin, 1994).

Conversely, adaptive antibiotic resistance describes a form of transient resistance that occurs due to the organism's ability to adapt and phenotypically modify itself in order to develop resistance to certain stressors (Barclay and Begg, 2001), where pre-exposure to antibiotics remains a major cause of resistance. Adaptive mechanisms include expression of efflux pumps, reduced number of porins and other cell surface modifications created by stress of low level antibiotics. Adaptive resistance is ephemeral type of resistance and bacteria tend to come to its original state once the stressor is removed. However, a longer pre-exposure to sub-inhibitory levels of antibiotics can result in the emergence of permanent mutations.

Materials and Methods

Sampling

A total of 69 samples were collected from different groups viz. human (32 urine samples), pig (20 faecal samples) and poultry (17 faecal samples).

Isolation and identification of bacterial

strains

After overnight enrichment of samples, cultures were streaked on to MacConkey agar. The plates of MacConkey agar (MCA) were incubated at 37°C for 24 hours. The pink lactose fermenting colonies were further streaked on to Eosin Methylene Blue (EMB) agar and incubated at 37°C for 24 hours.

The bacterial isolates showing characteristic metallic sheen were assigned laboratory numbers accordingly and confirmation of the isolates as *Escherichia coli* was done using Gram's staining, Catalase test, Oxidase test and a set of 25 biochemical tests provided in Hi 25 *Enterobacteriaceae* identification kit.

Antibiotic sensitivity test

The isolates were inoculated in sterile 5 ml nutrient broth, incubated for 18 hr at 37°C and then optical density was adjusted to 0.5 McFarland with Normal saline solution (Quinn *et al.*, 1994).

Each inoculum was then spread over the surface of Mueller-Hinton agar with the help of sterile swab. Plates were allowed to dry for 10 min at 37°C and then antibiotic discs were carefully placed on the surface with enough space around each disc for diffusion of the antibiotic.

Plates were incubated for 24 hr at 37°C and the zone of inhibition of growth of the organism around each disc was measured in millimeters. The antibiotic discs used for the experiment are given in table 1.

Ethidium bromide-agar (Et-br) cartwheel method for evaluation of MDR strains

The test was performed as per the method of Martins *et al.*, 2013.

Principle

This is a subjective screening test in which it is assumed that the smallest concentration of Et-br that produces fluorescence of the bacterial mass represents the highest concentration of Et-br that the bacteria can exclude.

The extent of exclusion is based on either active efflux pumps which will pump out the ethidium bromide or reduction in the number of porins thereby preventing the entry of ethidium bromide.

Ethidium Bromide (Et-br) agar Cartwheel method

All isolates were grown in 5 ml of nutrient broth and adjusted to 0.5 McFarland with PBS.

Agar plates containing Et-br concentrations ranging from 0.5 to 2.5 mg/l were prepared on the same day of the experiment and protected from light by covering with aluminium foil.

The plates were then divided into as many as 8 sectors by radial lines (cartwheel pattern).

Cultures were swabbed on Et-br agar plates starting from the centre of the plate and spreading towards the edges.

The swabbed Et-br agar plates were then incubated at 37°C for 16 h and examined under UV transilluminator and photographed.

The minimum concentration of Et-br that produced fluorescence was recorded.

Evaluation of MDR *E. coli* isolates for adaptive resistance

All the isolates were sub-cultured for five times in nutrient broth. After each sub-culturing antibiotic sensitivity test and

Ethidium bromide-agar (Et-br) cartwheel test were performed.

Results and Discussion

A total of 42 MDR *E. coli* isolate from humans, pigs and poultry were studied.

Antibiogram study for *Escherichia coli*

In the present investigation, all 42 *E. coli* isolates were subjected to resistotyping with 29 different antibiotics (Table 1). The response of organisms was interpreted as sensitive, intermediate and resistant based on the CLSI guidelines. The percentage of resistance of all the isolates to a particular antibiotic is given in Table 2.

The antibiotics tested belonged to various groups i.e. β -lactam antibiotics, aminoglycosides, glycopeptides, phenicoles, quinolones, Tetracyclines, sulphonamide, RNA synthesis inhibitor, polypeptides, macrolides and lincosamides. β -lactam antibiotics included penicillins, cephalosporins, monobactams and carbapenems.

In β -lactum group (cell wall synthesis inhibitors) all the isolates were resistant to Penicillin-G and Oxacillin.

Other antibiotics studied in this group were representatives of all the four generations of Cephalosporins, Ampicillin, Ticarcillin, Pipracillin, Polymyxin-B, Aztreonam, Meropenam and Vancomycin. Of the above studied antibiotics there was comparatively more resistance observed for first (95.2%) and second generation (90.5%) cephalosporins and vancomycin (97.6%). Human isolates had more resistance (95% and 70%) for third and fourth generation cephalosporins i.e. Ceftazidime and Cefepime also, as compared to pig and poultry isolates. Pig isolates were

least resistant with 58.3% and 16.7% resistivity to third and fourth generation cephalosporins respectively. On the contrary 60% and 50% poultry isolates were resistant to third and fourth generation cephalosporins respectively. Similarly, human and poultry isolates were more resistant to Ampicillin, Ticarcillin and Pipracillin (65%, 65%, 70% and 60%, 40%, 60% respectively) as compare to pig isolates (33.3%, 0% and 8.3% respectively). The resistivity patterns observed could be because of the difference in the antibiotic use of the hosts from which *E. coli* had been isolated. Since, history of the antibiotics being used in different hosts could not be collected no conclusive correlation could be obtained. Vancomycin has never been reported to be effective against *E. coli* as these Gram negative organisms have an intact outer membrane, which serves as a permeability barrier that blocks access of the antibiotic to the PG-D-Ala-D-Ala termini in the periplasm (Walsh *et al.*, 1996). There were 60% of *E. coli* isolates of human and poultry origin resistant to Meropenam and 25% isolates of pigs resistant to this antibiotic. Increased resistance to Meropenam is a point of concern as carbapenems are considered to be the ultimate drugs for the treatment of untreatable infections. Reasons for the resistance to these antibiotics could be the presence of active efflux, reduction in the number of porins or due to the activity of carbapenamases (Little *et al.*, 2012).

Four antibiotics of aminoglycoside group were taken for the present study namely: Streptomycin, Gentamicin, Kanamycin and Amikacin. Isolates of *E. coli* from three species taken for the study showed variable resistivity patterns to all the antibiotics of these four groups. Isolates of human and pig origin were sensitive to Streptomycin as compared to poultry isolates. But, for Gentamicin, all the poultry isolates were sensitive where as 45% and 25% resistance

was observed for human and pig isolates respectively. In case of Kanamycin high level of resistance was observed for human and poultry isolates (90% and 80% respectively). 95% of human isolates were resistant to Amikacin but only 41.7% and 40% pig and poultry isolates respectively were resistant.

In general, five mechanisms of resistance have been reported for this class of antibiotics: (i) decreased intracellular accumulation of the antibiotic by alteration of outer membrane permeability, diminished inner membrane transport or active efflux (ii) enzymatic modification of the drug, which is the most common (iii) modification of the target by mutation in ribosomal proteins or 16S rRNA genes (iv) trapping of the drug and (v) post transcriptional methylation of rRNA, using S-adenosyl-methionine as a cofactor (Magnet and Blanchard, 2005). Significant difference in resistivity observed for different antibiotics in relation to the species from which they were isolated indicate that this could be the affect of difference in the usage of the antibiotic and adaptive resistance rather than any other mechanism.

Human and pig isolates showed lower level of resistance to Tetracycline (30% and 8.3%) and Doxycycline (20% and 0%) as compared to poultry isolates (90% and 80%). Higher antibiotic resistivity of *E. coli* isolates from poultry to tetracyclins was also observed earlier in this region (Meena, 2015). Significant difference in resistivity pattern of human and pig *E. coli* isolates from poultry isolates clearly indicate Tertacyclin abuse in the poultry. The most common mechanism for resistance to the Tetracyclines is energy-dependent drug efflux. This energy-dependent drug efflux resistance can be transient, or by chromosomal mutations resulting in over expression of existing chromosomal genes *mexA*, *mexB*, *oprM* and *mar* (Table 3 and 4).

Table.1 List of antibiotics used for antibiogram study against *E. coli*

Cell wall synthesis inhibitor		
Class of antibiotics	Antibiotics	Concentration (mcg)
1 st gen. Cephalosporin	Cefazolin(CZ)	30
2 nd gen. Cephalosporin	Cefuroxime(CXM)	30
3 rd gen.cephaloantipseudo	Ceftazidime(CAZ)	30
3 rd gen. Cephalosporin	Cefotaxime(CTX)	30
4 th gen. Cephalosporin	Cefipime(CPM)	30
Natural penicillin	Penicillin-G(P)	10
Penicillinase stable	Oxacillin(OX)	1
Aminopenicillin	Ampicillin(AMP)	10
Carboxypenicillin	Ticarcillin(TI)	10
Ureidopenicillin	Pipracillin(PI)	100
Polypeptide	Polymyxin-B(PB)	300
Monobactams	Aztreonam(AT)	30
Carbapenems	Meropenam(MRP)	10
Glycopeptides	Vancomycin (VA)	30
Protein synthesis inhibitor (30-S)		
Aminoglycoside	Kanamycin(K)	30
Aminoglycoside	Gentamicin(GEN)	10
Aminoglycoside	Amikacin(Ak)	30
Aminoglycoside	Streptomycin(S)	10
Natural tetracycline	Tetracycline(TE)	30
Semisynthetic tet.	Doxycycline(DO)	30
Protein synthesis inhibitor (50-S)		
Lincosamides	Clindamycin(CD)	2
Macrolides(50-S)	Erythromycin(E)	15
Phenicoles(50-S)	Chloramphenicol(C)	30
DNA synthesis inhibitor		
1 st gen quinolone	Nalidixic acid(NA)	30
2 nd gen quinolone	Ciprofloxacin(CIP)	5
3 rd gen quinolone	Levofloxacin(LE)	5
RNA synthesis inhibitor		
RNA synthesis inhibitor	Rifampicin(RIF)	5
Anti metabolite antibiotics (folic acid synthesis inhibitors)		
Sulphonamide	Trimethoprim(TR)	5
Combination of sulpha + trimethoprim	Cotrimoxazole(COT)	25

Table.2 Percent resistivity of all the 42 isolates of *Escherichia coli* to a given antibiotic

Mechanism	Class of antibiotics	Antibiotics	Sensitive (%)	Intermediate (%)	Total Resistant <i>E. Coli</i> (%)	Resistant <i>E. coli</i> from Human (%)	Resistant <i>E. coli</i> from Pig (%)	Resistant <i>E. coli</i> from Poultry (%)
Cell wall Synthesis Inhibitor	1 st gen. Cephalosporin	Cefazolin	2.4	2.4	95.2	100	91.6	90
	2 nd gen. Cephalosporin	Cefuroxime	2.4	7.1	90.5	80	100	100
	3 rd gen. cephaloantipseudo	Ceftazidime	16.7	7.1	76.2	95	58.3	60
	3 rd gen. Cephalosporin	Cefotaxime	11.9	21.4	66.7	85	58.3	40
	4 th gen. Cephalosporin	Cefepime	38.1	11.9	50	70	16.7	50
	Natural penicillin	Penicillin-G	0	0	100	100	100	100
	Penicillinase stable	Oxacillin	0	0	100	100	100	100
	Aminopenicillin	Ampicillin	33.3	11.9	54.8	65	33.3	60
	Carboxypenicillin	Ticarcillin	47.6	11.9	40.5	65	0	40
	Ureidopenicillin	Pipracillin	26.2	23.8	50	70	8.3	60
	Polypeptide	Polymyxin-B	50	0	50	40	50	70
	Monobactams	Aztreonam	35.7	26.2	38.1	65	8.3	20
	Carbapenems	Meropenam	31	19	50	60	25	60
	Glycopeptides	Vancomycin	0	2.4	97.6	95	100	100
Protein Synthesis Inhibitor (30-S)	Aminoglycoside	Kanamycin	0	26.2	73.8	90	41.7	80
	Aminoglycoside	Gentamicin	54.8	16.7	28.6	45	25	0
	Aminoglycoside	Amikacin	19	14.3	66.7	95	41.7	40
	Aminoglycoside	Streptomycin	40.5	40.5	19	15	8.3	40
	Natural tetracycline	Tetracycline	54.8	7.1	38.1	30	8.3	90
	Semisynthetic tetracycline	Doxycycline	61.9	9.5	28.6	20	0	80
Protein Synthesis inhibitor (50-S)	Lincosamides	Clindamycin	0	0	100	100	100	100
	Macrolides	Erythromycin	0	4.8	95.2	90	100	100
	Phenicoles	Chloramphenicol	78.6	9.5	11.9	15	0	20
DNA synthesis Inhibitor	1 st gen quinolone	Nalidixic acid	21.4	16.7	61.9	55	58.3	80
	2 nd gen quinolone	Ciprofloxacin	47.6	19	33.3	55	0	30
	3 rd gen quinolone	Levofloxacin	59.5	14.3	26.2	50	0	10
RNA inhibitor	RNA synthesis inhibitor	Rifampicin	0	0	100	100	100	100
Antimetabolite	Sulphonamide	Trimethoprim	54.8	2.4	42.9	65	0	50
	Sulpha + trimethoprim	Cotrimoxazole	54.8	0	45.2	65	0	60

Table.3 Antibigram of different isolates of *Escherichia coli* from human

Class of antibiotics	Antibiotics	HU 2	HU 3	HU 4	HU 7	HS 10	HU 12	HU 13	HU 14	HU 15	HU 17	HU 18	HU 20	HU 22	HU 23	HU 24	HU 27	HU 29	HU 30	E.H	E. J
1 st gen. Cephalosporin	Cefazolin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
2 nd gen. Cephalosporin	Cefuroxime	S	R	R	R	R	I	R	I	I	R	R	R	R	R	R	R	R	R	R	R
3 rd gen. Cephalosporin	Ceftazidime	I	R	R	R	R	R	R	R*	R	R	R	R	R	R	R	R	R	R	R	R
3 rd gen. Cephalosporin	Cefotaxime	R	R	I	R	R	R	R	I**	I	R	R	R	R	R	R	R	R	R	R	R
4 th gen. Cephalosporin	Cefipime	S	R	R	R	R	I	S	S***	S	R	R	R	R	R	R	R	R	R	R	I
Natural penicillin	Penicillin-G	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Penicillinase stable	Oxacillin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Aminopenicillin	Ampicillin	S	I	S	S	R	S	R	S	R	R	R	R	R	R	R	R	R	R	I	R
Carboxypenicillin	Ticarcillin	S	S	S	R	R	S	R	S	S	R	R	R	R	R	R	R	R	R	I	R
Ureidopenicillin	Pipracillin	S	I	S	R	R	I	R	S	S	R	R	R	R	R	R	R	R	R	R	R
Polypeptide	Polymyxin-B	R	R	R	R	S	R	S	S	R	S	S	S	S	S	S	R	S	S	S	R
Monobactams	Aztreonam	S	R	S	I	R	S	S	I	R	R	R	R	R	R	R	R	R	R	I	R
Carbapenems	Meropenam	S	S	S	I	R	S	R	S	R	R	R	R	R	R	R	R	R	R	I	S
Glycopeptides	Vancomycin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Aminoglycoside	Kanamycin	R	R	I	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	I	R
Aminoglycoside	Gentamicin	I	S	S	I	S	I	I	S	I	R	R	R	R	R	R	R	R	R	S	I
Aminoglycoside	Amikacin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	I	R
Aminoglycoside	Streptomycin	I	I	S	R	I	I	R	S	I	S	S	S	S	S	S	S	S	S	I	R
Natural tetracycline	Tetracycline	S	S	S	R	R	I	R	R	S	S	S	S	S	S	S	I	S	S	R	R
Semisynthetic tetracycline	Doxycycline	I	S	S	R	R	S	R	I	S	S	S	S	S	S	S	S	S	S	R	S
Lincosamides	Clindamycin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Macrolides(50-S)	Erythromycin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	I	I
Phenicoles(50-S)	Chloramphenicol	R	S	R	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	R
1 st gen quinolone	Nalidixic acid	S	I	S	I	R	S	I	S	S	R	R	R	R	R	R	R	R	R	R	S
2 nd gen quinolone	Ciprofloxacin	S	S	S	S	S	S	R	S	S	R	R	R	R	R	R	R	R	R	I	R
3 rd gen quinolone	Levofloxacin	S	S	S	I	S	S	I	S	R	R	R	R	R	R	R	R	R	R	S	I
RNA synthesis inhibitor	Rifampicin	R	R	S	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Sulphonamide	Trimethoprim	S	S	S	R	R	S	R	S	S	R	R	R	R	R	R	R	R	R	R	S
Combination of sulpha + trimetho.	Cotrimoxazole	S	S	S	R	R	S	R	S	S	R	R	R	R	R	R	R	R	R	R	S

*R = Resistant, **I = Intermediate, ***S = Sensitive

Table.4 Antibigram of different isolates of *Escherichia coli* from pig and poultry

Class of antibiotics	Antibiotics	P 2	P 4	P 5	P 6	P 9	P 10	P 12	P 15	P 16	P 19	P 21	P 22	Pou F2	Pou F3	Pou F4	Pou S9	PouS 10	PouS 11	PouS 12	PouS 13	PouS 14	PouS 15
1 st gen. cephalosporin	Cefazolin	R	R	R	R	R	R	R	R	R	R	R	S	R	I**	R	R	R	R	R	R	R	R
2 nd gen. cephalosporin	Cefuroxime	R	R	R	R	R	R	R	R	R	R	R	R	R	R*	R	R	R	R	R	R	R	R
3 rd gen. cephalosporin	Ceftazidime	I	R	R	R	R	S	R	R	I	S	R	S	R	S***	R	S	R	R	S	S	R	R
3 rd gen. cephalosporin	Cefotaxime	R	R	I	R	I	I	R	I	S	R	R	R	R	S	I	S	R	R	S	R	S	I
4 th gen. cephalosporin	Cefipime	S	S	R	S	S	S	S	S	S	R	I	S	R	S	S	S	R	I	I	R	R	R
Natural penicillin	Penicillin-G	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Penicillinase stable	Oxacillin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Aminopenicillin	Ampicillin	S	I	S	R	R	R	I	I	R	S	S	S	R	S	S	S	R	R	S	R	R	R
Carboxypenicillin	Ticarcillin	S	I	I	I	S	S	S	S	S	I	S	S	R	S	S	S	R	R	S	S	S	R
Ureidopenicillin	Pipracillin	S	I	I	R	I	S	S	I	S	I	I	I	R	S	S	I	R	R	I	R	R	R
Polypeptide	Polymyxin-B	R	S	S	R	R	S	S	S	S	R	R	R	R	S	S	R	S	R	R	R	R	R
Monobactams	Aztreonam	I	S	S	S	I	S	I	I	S	R	I	I	R	S	S	S	R	I	S	S	I	S
Carbapenems	Meropenam	S	I	S	R	I	S	R	S	I	I	I	R	S	R	R	R	I	R	S	R	R	S
Glycopeptides	Vancomycin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Aminoglycoside	Kanamycin	I	I	R	R	I	I	I	R	I	R	R	I	I	R	R	I	R	R	R	R	R	R
Aminoglycoside	Gentamicin	R	S	R	R	S	S	S	S	S	S	S	S	S	S	S	S	I	S	S	S	S	S
Aminoglycoside	Amikacin	I	S	I	R	I	R	R	I	R	I	R	S	S	S	R	S	S	R	S	R	R	S
Aminoglycoside	Streptomycin	I	I	I	I	I	S	I	I	I	S	R	S	I	R	R	S	I	R	S	R	S	I
Natural tetracycline	Tetracycline	S	S	S	S	S	S	R	S	S	S	S	S	R	R	R	I	R	R	R	R	R	R
Semisynthetic tetracycline	Doxycycline	S	S	S	S	S	S	S	S	S	S	S	S	R	R	R	I	R	R	R	R	I	R
Lincosamides	Clindamycin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Macrolides(50-S)	Erythromycin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Phenicoles(50-S)	Chloramphenicol	S	S	S	S	S	S	S	S	S	I	I	S	I	S	S	S	R	R	S	I	S	S
1 st gen quinolone	Nalidixic acid	I	I	R	R	R	R	S	I	I	R	R	R	R	R	R	S	R	R	S	R	R	R
2 nd gen quinolone	Ciprofloxacin	S	S	S	S	S	S	I	S	I	S	I	S	I	I	R	S	I	R	S	I	S	R
3 rd gen quinolone	Levofloxacin	S	S	S	S	S	S	S	S	S	S	S	I	S	S	R	S	S	S	S	S	I	S
RNA synthesis inhibitor	Rifampicin	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Sulphonamide	Trimethoprim	S	S	S	S	S	S	I	S	S	S	S	S	R	R	S	S	R	R	S	R	S	S
Combination of sulpha + trimetho.	Cotrimoxazole	S	S	S	S	S	S	S	S	S	S	S	S	R	R	S	S	R	R	S	S	R	R

*R = Resistant, **I = Intermediate, ***S = Sensitive

Table.5 Intensity of florescence of different *Escherichia coli* isolates at different concentrations of Ethidium Bromide

Intensity	Isolates not showing fluorescence	Isolates showing florescence
Result of florescence at 0.5 mg/l concentration		
Human	HU2, HU4, HU7, HU12, HU13, HU15, HU17, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.H.	HU3, HS10, HU14, E.J.
Pig	P2, P4, P10, P12, P15, P19, P21, P22	P5, P6, P9, P16
Poultry	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS12, PouS13, PouS14, PouS15	NIL
Result of florescence at 1 mg/l concentration		
Human	HU2, HU7, HU17, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.H.	HU3, HU4, HS10, HU12, HU13, HU14, HU15, E.J.
Pig	P2, P4, P10, P12, P15, P21	P5, P6, P9, P16, P19, P22
Poultry	PouF2, PouF3, PouF4, PouS9, PouS10, PouS12, PouS14	PouS11, PouS13, PouS15
Result of florescence at 1.5 mg/l concentration		
Human	HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, E.J., E.H.
Pig	P2, P4, P12, P15	P5, P6, P9, P10, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2mg/l concentration		
Human	HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, E.J., E.H.
Pig	P12, P15	P2, P4, P5, P6, P9, P10, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2.5 mg/l concentration		
Human	HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15

Table.6 Antibigram of different isolates of *Escherichia coli* on Sub-culturing

Subc ulture	HU-2							HU-3							HU-4							HU-7						
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E
Sub-1	I	S	I	I	R	I	S	S	S	R	S	S	R	S	S	R	S	R	I	R	I	R	R	S	S	I	R	I
Sub-2	I	S	I	S	R	S	S	S	S	I	S	S	R	S	S	S	S	S	I	R	S	R	R	S	S	S	R	S
Sub-3	I	S	I	S	I	S	S	S	S	S	S	S	R	S	S	S	S	S	I	R	S	R	R	R	S	S	R	S
Sub-4	I	S	S	S	I	S	S	S	S	S	S	S	R	S	S	S	S	S	I	R	S	R	R	R	S	S	R	S
Sub-5	I	S	S	S	S	S	S	S	S	S	S	S	R	S	S	S	S	S	I	R	S	R	R	R	S	S	R	S

Subc ulture	HS-10							HU-12							HU-13							HU-14						
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E
Sub-1	R	R	R	S	R	R	S	R	S	R	I	R	S	I	R	R	R	S	R	S	I	R	S	S	S	I	R	S
Sub-2	R	R	R	S	R	R	S	S	S	I	S	I	S	S	R	R	R	S	R	S	I	R	S	S	S	S	R	S
Sub-3	R	R	R	S	S	R	S	S	S	I	S	S	S	S	R	R	R	S	R	S	I	R	S	S	S	S	R	S
Sub-4	R	R	R	S	S	R	S	S	S	I	S	S	S	S	R	R	R	S	R	S	I	R	S	S	S	S	R	S
Sub-5	R	R	R	S	S	R	S	S	S	I	S	S	S	S	R	R	R	S	I	S	S	R	S	S	S	S	R	S

Subc ulture	HU-15							HU-17							HU-18							HU-20						
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E
Sub-1	S	S	S	S	I	R	S	S	R	R	S	R	R	R	I	R	R	S	R	R	R	I	R	R	S	R	R	R
Sub-2	S	S	S	S	I	R	S	S	R	R	S	R	R	R	I	R	R	S	R	R	R	S	R	R	S	R	R	R
Sub-3	S	S	S	S	S	R	S	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R
Sub-4	S	S	S	S	S	R	S	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R
Sub-5	S	S	S	S	S	I	S	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R

Subculture	HU-22							HU-23							HU-24							HU-27							
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	
Sub-1	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	S	R	R	S	R	R	R
Sub-2	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	S	R	R	S	R	R	R
Sub-3	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	S	R	R	S	R	R	R
Sub-4	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	S	R	R	S	R	R	R
Sub-5	S	R	R	S	R	R	R	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	S	R	R	S	R	R	R
Subculture	HU-29							HU-30							E.Coli H							E.Coli J							
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	
Sub-1	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	R	R	S	R	R	S	S	S	R	I	S	S	S	
Sub-2	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	R	R	S	R	R	S	S	S	I	I	S	S	S	
Sub-3	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	R	R	S	R	R	S	S	S	I	I	S	S	S	
Sub-4	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	R	R	S	R	R	S	S	S	I	S	S	S	S	
Sub-5	S	R	R	S	R	R	R	S	R	R	S	R	R	R	R	R	R	S	R	R	S	S	S	I	S	S	S	S	
Subculture	P-2							P-4							P-5							P-6							
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	
Sub-1	I	I	R	I	S	R	S	S	S	R	S	I	S	S	S	S	R	S	I	S	S	S	S	R	S	I	I	S	
Sub-2	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S	
Sub-3	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S	
Sub-4	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S	
Sub-5	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S	

Sub culture	P-9							P-10							P-12							P-15							
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	
Sub-1	S	S	R	S	I	S	S	I	S	R	S	R	R	S	S	S	R	S	I	S	S	S	S	S	R	S	S	S	S
Sub-2	S	S	R	S	I	S	S	S	S	I	S	S	S	S	S	S	I	S	I	S	S	S	S	I	S	S	S	S	
Sub-3	S	S	R	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	
Sub-4	S	S	R	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	S	S	S	S	S	
Sub-5	S	S	R	S	S	S	S	S	S	I	S	S	S	S	S	S	I	S	S	S	S	S	S	S	S	S	S	S	

Subculture	P-16							P-19							P-21							P-22						
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E
Sub-1	S	S	I	S	S	S	S	S	S	R	S	R	S	S	S	S	I	S	S	S	S	I	S	R	S	S	S	S
Sub-2	S	S	I	S	S	S	S	S	S	R	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S
Sub-3	S	S	I	S	S	S	S	S	S	R	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S
Sub-4	S	S	I	S	S	S	S	S	S	R	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S
Sub-5	S	S	I	S	S	S	S	S	S	R	S	S	S	S	S	S	I	S	S	S	S	S	S	R	S	S	S	S

Subculture	PouF-2							PouF-3							PouF-4							PouS-9						
	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E	T E	C O	A M P	C	M R P	C P M	L E
Sub-1	R	S	R	S	I	R	S	R	R	R	S	I	R	S	R	S	R	S	I	R	S	R	S	I	S	S	S	S
Sub-2	R	S	R	S	I	R	S	R	R	R	S	I	R	S	R	S	R	S	I	I	S	R	S	I	S	S	S	S
Sub-3	R	S	R	S	I	R	S	R	R	I	S	I	R	S	R	S	S	S	I	I	S	R	S	I	S	S	S	S
Sub-4	R	S	R	S	I	R	S	R	R	I	S	I	R	S	R	S	S	S	I	I	S	R	S	I	S	S	S	S
Sub-5	R	S	R	S	I	R	S	R	R	I	S	I	R	S	R	S	S	S	I	I	S	R	S	I	S	S	S	S

Subculture	PouS-10							PouS-11							PouS-12							PouS-13						
	TE	CO	AMP	C	MRP	CPM	LE	TE	CO	AMP	C	MRP	CPM	LE	TE	CO	AMP	C	MRP	CPM	LE	TE	CO	AMP	C	MRP	CPM	LE
Sub-1	R	R	R	R	I	R	S	R	R	R	I	I	R	S	R	S	I	S	S	I	S	R	S	R	I	R	R	I
Sub-2	R	R	R	S	I	R	S	R	R	R	S	I	R	S	R	S	I	S	S	S	S	I	S	R	S	S	R	S
Sub-3	R	R	R	S	S	R	S	R	R	R	S	I	R	S	R	S	I	S	S	S	S	I	S	S	S	S	R	S
Sub-4	R	R	R	S	S	R	S	R	R	R	S	I	R	S	R	S	I	S	S	S	S	I	S	S	S	S	R	S
Sub-5	R	R	R	S	S	R	S	R	R	R	S	I	R	S	R	S	I	S	S	S	S	I	S	S	S	S	R	S

Subculture	PouS-14							PouS-15						
	TE	CO	AMP	C	MRP	CPM	LE	TE	CO	AMP	C	MRP	CPM	LE
Sub-1	R	R	R	S	R	R	I	R	R	I	S	I	R	S
Sub-2	R	R	R	S	R	R	I	R	R	I	S	S	R	S
Sub-3	R	R	R	S	R	R	S	R	R	I	S	S	R	S
Sub-4	R	R	R	S	R	R	S	R	R	I	S	S	R	S
Sub-5	R	R	R	S	R	R	S	R	R	I	S	S	R	S

*S – Sensitive

*R – Resistant

*TE –Tetracycline

*CO – Cotrimoxazole

*LE – Levofloxacin

*I – Intermediate

*C – Chloramphenicol

*MRP – Meropenam

*CPM– Cefepime

*AMP – Ampicillin

Table.7 Number of *E. coli* isolate showing decrease in resistance on different sub culturing against tested group of antibiotics

S. No	Name of antibiotics	No. of isolates (2 nd sub culture)	No. of isolates (3 rd sub culture)	No. of isolates (4 th sub culture)	No. of isolates (5 th sub culture)	Total isolate
1.	Meropenam	11	5	1	0	17
2.	Ampicillin	6	7	1	0	14
3.	Chloramphenicol	7	0	1	0	8
4.	Cefepime	6	0	0	1	7
5.	Tetracycline	6	1	0	0	7
6.	Levofloxacin	4	1	1	0	6
7.	Co-trimoxazole	2	0	0	0	2

Table.8 Intensity of florescence of different *E. coli* isolates at different concentrations of Et-br after 1st sub culturing

Intensity	Isolates not showing fluorescence	Isolates showing fluorescence
Result of florescence at 0.5 mg/l concentration		
Human	HU2, HU4, HU7, HU17, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.H.	HU3, HS10, HU12, HU13, HU14, HU15, E.J.
Pig	P2, P4, P10, P12, P15	P5, P6, P9, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1 mg/l concentration		
Human	HU2, HU7, HU17, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.H.	HU3, HU4, HS10, HU12, HU13, HU14, HU15, E.J.
Pig	P2, P4, P10, P12, P15	P5, P6, P9, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1.5 mg/l concentration		
Human	HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, E.J., E.H.
Pig	P2, P4, P12, P15	P5, P6, P9, P10, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2mg/l concentration		
Human	HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, E.J., E.H.
Pig	P12, P15	P2, P4, P5, P6, P9, P10, P16, P19, P21, P22
Poultry	PouS12	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2.5 mg/l concentration		
Human	HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	NIL	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS12, PouS13, PouS14, PouS15

Table.9 Intensity of florescence of different *E. coli* isolates at different concentrations of Et-br after 2nd sub culturing

Intensity	Isolates not showing fluorescence	Isolates showing fluorescence
Result of florescence at 0.5 mg/l concentration		
Human	HU2, HU4, HU17, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.H.	HU3, HU7, HS10, HU12, HU13, HU14, HU15, E.J., E.H.
Pig	P2, P4, P10, P12, P15	P5, P6, P9, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1 mg/l concentration		
Human	HU2, HU17, HU20, HU22, HU23, HU24, HU27, HU29, HU30,	HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU18, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1.5 mg/l concentration		
Human	HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS12	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2.5 mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	NIL	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS12, PouS13, PouS14, PouS15

Table.10 Intensity of florescence of different *E. coli* isolates at different concentrations of Et-br after 3rd sub culturing

Intensity	Isolates not showing fluorescence	Isolates showing fluorescence
Result of florescence at 0.5 mg/l concentration		
Human	HU2, HU17, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.H.	HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, E.J., E.H.
Pig	P2, P4, P10, P12, P15	P5, P6, P9, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1 mg/l concentration		
Human	HU17, HU22, HU23, HU24, HU27, HU29, HU30,	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU18, HU20, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1.5 mg/l concentration		
Human	HU27, HU29, HU30	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS12	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2.5 mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	NIL	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS12, PouS13, PouS14, PouS15

Table.11 Intensity of florescence of different *E. coli* isolates at different concentrations of Et-br after 4th sub culturing

Intensity	Isolates not showing fluorescence	Isolates showing fluorescence
Result of florescence at 0.5 mg/l concentration		
Human	HU17, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.H.	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, E.J, E.H.
Pig	P2, P4, P10, P12, P15	P5, P6, P9, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1 mg/l concentration		
Human	HU17, HU22, HU23, HU24, HU27, HU29, HU30,	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU18, HU20, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1.5 mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS12	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2.5 mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	NIL	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS12, PouS13, PouS14, PouS15

Table.12 Intensity of florescence of different *E. coli* isolates at different concentrations of Et-br after 5th sub culturing

Intensity	Isolates not showing fluorescence	Isolates showing fluorescence
Result of florescence at 0.5 mg/l concentration		
Human	HU17, HU18, HU20, HU23, HU24, HU30, E.H.	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU22, HU27, HU29, E.J, E.H.
Pig	P2, P4, P10, P12, P15	P5, P6, P9, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1 mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU117, HU18, HU20, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 1.5 mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS9, PouS12	PouF2, PouF3, PouF4, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	PouS12	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS13, PouS14, PouS15
Result of florescence at 2.5 mg/l concentration		
Human	NIL	HU2, HU3, HU4, HU7, HS10, HU12, HU13, HU14, HU15, HU20, HU17, HU18, HU22, HU23, HU24, HU27, HU29, HU30, E.J., E.H.
Pig	NIL	P2, P4, P5, P6, P9, P10, P12, P15, P16, P19, P21, P22
Poultry	NIL	PouF2, PouF3, PouF4, PouS9, PouS10, PouS11, PouS12, PouS13, PouS14, PouS15

The product of these loci then function as a multidrug efflux pump with broad substrate specificity or, in the case of the *mar* locus, as a regulator to control expression of at least one membrane efflux system, *acrAB* (Ross *et al.*, 1998).

All the members of *Enterobacteriaceae* are intrinsically resistant (100%) to RNA inhibitor Rifampicin as the RNA polymerase of *E. coli* is 1000 fold less sensitive to Rifampicin as compared to that of *M. tuberculosis* (Zenkin *et al.*, 2005). This may be the reason that all isolates were resistant to Rifampicin. For Trimethoprim 65% of human and poultry isolates were resistant. Although, initially Trimethoprim was effective against *E. coli* and was effectively used in the treatments of Urinary Tract Infections caused by *E. coli* but its extensive use selected for resistant strains. In *E. coli*, trimethoprim-sulfamethoxazole resistance often correlates with the presence of dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genes in integrons (Rasheed *et al.*, 2014). Even though there has been drastic decrease in the use of trimethoprim but the low fitness cost of trimethoprim resistance and its ease of spread with the integrons has made least effect on its resistance (Brolund *et al.*, 2010). All the pig isolates were sensitive to this antibiotic.

The fluoroquinolone antibiotics were considered to be critical antibiotics due to their very high effectiveness against pathogens that are resistant to other antibiotics (Olorunmola *et al.*, 2013). In present study for the quinolone group of antibiotics (DNA synthesis inhibitors) 61.9%, 33.3% and 26.2% isolates were resistant for Nalidixic acid, Ciprofloxacin and Levofloxacin respectively (Table 2). In an earlier study, the strains with intermediate resistance to ciprofloxacin were reported to have a single mutation in *gyrA* or *gyrA* and

parC genes, and strains with complete resistance to ciprofloxacin had double and single mutations in *gyrA* and *parC*, respectively (Guerra *et al.*, 2003). In the present study it was also found that there were low levels of resistance (13.6% and 4.5%) in pig and poultry (30% and 10%) isolates for Ciprofloxacin and Levofloxacin as compared to human isolates (55% and 50%). Quinolones are drug of choice for the urinary tract infections (UTI). Since there were isolates of *E. coli* from patients with UTI it could be the probable reason for resistance towards this group of antibiotics.

Ethidium bromide agar (Et-br) cartwheel test based evaluation of MDR strains

The results of Ethidium bromide agar (Et-br) cartwheel method for evaluation of MDR is given in Table 5. At a concentration of 0.5 mg/l, 81% of the isolates resisted the entry of Et-br. But at the higher concentration of Et-br i.e. 1mg/l to 2.5 mg/l there was uptake of Et-br in a dose dependent manner and more isolates started to show florescence. But, there were ten isolates i.e. HU-17, HU-18, HU-22, HU-23, HU-24, HU-27, HU-29, HU-30, PouF-9 and PouF-12 which could resist the uptake of Et-br even at a dose of 2.5mg/l.

This test is a subjective test where exclusion of the Et-br by the bacterial isolates leads to no florescence and vice-versa. The extent of exclusion is indicative of the capability of an isolate to prevent the entry of antibiotics. In this approach, higher the concentration of Et-br required to produce fluorescence of the bacterial mass, greater is the capacity of the bacterial cells to resist higher concentrations of antibiotics also. This test can be used as an assessment test for methods of resistance in MDR phenotype bacteria. The prevention of the entry may be because of the active efflux pump activity due to which the Et-br is actively pumped out of the bacterial cell or it

may be because of the decrease in the number of porins which otherwise are the sites of drug entry in a bacterial isolate (Martins *et al.*, 2013). Based on the above results it could be deduced that the above ten isolates had higher capacity to prevent the entry of antibiotics.

Evaluation of MDR *E. coli* isolates for adaptive resistance

All the 42 *E. coli* isolates were sub-cultured five times to see whether the withdrawal of antibiotics had any effect on the resistivity of the isolates and permeability of Et-br and at which level. To study resistivity patterns seven antibiotics were taken namely: Tetracycline, Chloramphenicol, Ampicillin, Cefepime, Meropenem, Levofloxacin and Cotrimoxazole. In majority of the isolates positive effect of withdrawal of antibiotic was observed. The isolates became sensitive to an antibiotic either on second or third sub-culturing but not on first sub-culture. No significant change in pattern was observed post third sub culturing. But, the extent of sensitivity varied for different antibiotics on the isolates irrespective of the source of the isolates i.e. human, pig or poultry. All the isolates behaved as an independent identity. To deduce a uniform pattern, so that overall effect of a given antibiotic could be studied the results of each isolate were evaluated against a given antibiotic. Effect of sub-culturing was observed maximum for Meropenem where a total of 17 isolates showed the positive effect in terms of increased sensitivity followed by Ampicillin (Table 6 and 7). It could be deduced that the withdrawal of antibiotic does have a positive effect on the resistance of bacteria. In a study to investigate the temporal occurrence and the genetic background of apramycin and gentamicin resistance in *Escherichia coli* strains from pork, duration of use and amounts of antibiotics used; both had a significant effect on the prevalence of

apramycin/gentamicin cross-resistance (Jensen *et al.*, 2006). Yet another study on influence of prophylactic and therapeutic antimicrobial administration on antimicrobial resistance of faecal *E. coli* in a dairy calves Berge *et al.*, 2006 reported transient effect of antibiotic on resistance.

To further assess whether the permeability of the isolates increased on sub-culturing in an antibiotic free environment, isolates were cultured in presence of Et-br. Sub-culturing had a positive effect on the permeability of Et-br as indicated by the fluorescence given by the bacteria post each sub culture (Table 8 to 12). The isolates initially resisting higher doses of Et-br on subsequent culturing became more permeable to higher doses of Et-br. Initially, there were ten isolates that were resisting high dose (2.5 mg/l) of Et-br. But by fifth sub-culturing none of the isolate was resisting the high dose (2.5 mg/l) of Et-br. There was only one isolate (PouS 12) which could resist dose of 2 mg/l on fifth sub-culturing. This clearly indicates that withdrawal of antibiotics had a drastic positive effect on the susceptibility of bacteria where almost all the isolates became permeable to even 1 mg/l dose of Et-br.

Reductions in prescribing antimicrobials have been reported to achieve specific, localized decreases in antimicrobial resistance (Barbosa and Levy, 2000). In Japan, erythromycin resistance decreased from 22.2% of clinical isolates to virtually 100% sensitivity over a 9-year-period following reduced macrolide consumption (Barbosa and Levy, 2000). Reduction of resistance following the removal of antimicrobial treatment is reported by Nys *et al.*, (2005) reported reduction of resistance following removal of antibiotic treatment. But, on the contrary, some studies have illustrated that resistance can persist over a prolonged period to antimicrobial agents no longer in common use (Enne *et al.*, 2001).

It depends on several factors whether the withdrawal of antibiotics will always have a positive effect. Therefore, from the present study, it can only be stated that under *in vitro* conditions there was a generalized positive effect of withdrawal on the permeability of isolates to Et-br but resistivity patterns indicate that this withdrawal has a selective effect.

Effect of sub-culturing in antibiotic free environment lead to positive effect on resistivity pattern, although it varied for different antibiotic for different isolates but the permeability of all the isolates increased uniformly to Et-br. It was concluded that each isolate has an independent identity and can adopt any mechanism present in it to resist the antibiotic toxicity but withdrawal of antibiotic helps in reverting the resistant phenotype towards being susceptible in majority of the MDRs under *in vitro* conditions.

Acknowledgement

I am thankful to Co-authors Prof. Sunil Maherchandani, Prof. S. K. Kashyap Department of Veterinary Microbiology & Biotechnology, Bikaner for his guidance, cooperation and persistent motivation during entire period of study.

References

- Barbosa, T.M. and Levy, S.B. (2000). The impact of antibiotic use on resistance development and persistence. *Drug Res. Updates* 3: 303–311.
- Barclay, M.L. and Begg, E.J. (2001). Aminoglycoside adaptive resistance: importance for effective dosage regimens. *Drugs*. 61: 713-721.
- Berge, A.C.B., Moore, D.A. and Sischo, W.M. (2006). Field Trial Evaluating the Influence of Prophylactic and Therapeutic Antimicrobial Administration on Antimicrobial Resistance of Fecal *Escherichia coli* in Dairy Calves. *Appl. Environ. Microbiol.* 72(6): 3872–3878.
- Brolund, A., Sundqvist, M., Kahlmeter, G. and Grape, M. (2010). Molecular Characterization of Trimethoprim Resistance in *Escherichia coli* and *Klebsiella pneumoniae* during a Two Year Intervention on Trimethoprim Use. *PLoS ONE*. 5(2): 9233.
- Courvalin, P. (1994). Transfer of antibiotic resistance genes between grampositive and gram-negative bacteria. *Antimicrob. Agents Chemother.* 38: 1447-1451.
- Enne, V.I., Livermore, D.M., Stephens, P. and Hall, L.M. (2001). Persistence of sulphonamide resistance in *Escherichia coli* in the UK despite national prescribing restriction. *Lancet*. 357: 1325–1328.
- Ganguly, N.K., Arora, N.K., Chandy, S.J., Fairuze, M.N., Gill, J.P.S., Gupta, U., Hossain, S., Joglekar, S., Joshi, P. C., Kakkar, M., Kotwani, A., Rattan, A., Sudarshan, H., Thomas, K., Wattal, C., Easton, A. and Laxminarayan, R. (2011). Rationalizing antibiotic use to limit antibiotic resistance in India. *J. Med. Res.* 134(3): 281-294.
- Guerra, B., Junker, E., Schroeter, A., Malorny, B., Lehmann, S. and Helmuth, R. (2003). Phenotypic and genotypic characterization of antimicrobial resistance in German *Escherichia coli* isolates from cattle, swine and poultry. *J. Antimicrob. Chemother.* 52(3): 489-492.
- Jensen, V.F., Jakobsen, L., Emborg, H., Seyfarth, A.M. and Hammerum, A.M. (2006). Correlation between apramycin and Gentamicin use in pigs and an increase reservoir of Gentamicin-resistant *Escherichia coli*. *J. Antimicrob. Chemother.* 58(1): 101.
- Laxminarayan, R. and Chaudhury, R.R. (2016). Antibiotic Resistance in India: Drivers and Opportunities for Action. *PLoS Med.* 13(3): e1001974.
- Little, M.L., Qin, X., Zerr, D.M. and Weissman, S.J. (2012). Molecular diversity in mechanisms of carbapenems resistance in

- paediatric Enterobacteriaceae. *Int. J. Antimicrob. Agents*. 39(1): 52-57.
- Magnet, S. and Blanchard, J.S. (2005). Molecular insights into aminoglycosides action and resistance. *Chem. Rev.* 105: 477-497.
- Martins, M., McCusker, M.P., Viveiros, M., Couto, I., Fanning, S., Pagès, J.M., and Amaral, L. (2013). A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps. *Open Microbiol. J.* 7(1): 72-82.
- Meena, H. (2015). Mechanism of antibiotic resistance in multidrug resistant commensal *Escherichia coli* isolated from poultry. M. V. Sc. Thesis submitted to the Rajasthan University of Veterinary and Animal Science, Bikaner.
- Nys, S., Bruinsma, N., Filius, P.M.G., van den Bogaard, A.E., Hoffman, L., Terporten, P.H.W., Wildeboer-Veloo, A.C.M., Degener, J., Endtz, H.P. and Stobberingh, E.E. (2005). Effect of hospitalisation on the antibiotic resistance of faecal *Enterococcus faecalis* of surgical patients over time. *Microbial Drug Resis.* 11: 154-158.
- Olorunmola, F.O., Kolawole, D.O. and Lamikanra, A. (2013). Antibiotic Resistance and Virulence Properties in *Escherichia coli* Strains from Cases of Urinary Tract Infections. *Afr. J. Infect. Dis.* 7(1): 1-7.
- Quinn, P.J., Carter, M.E., Markey, B.K. and Carter, G.R. (1994). *Clin. Vet. Microbiol.* Wolf Publishing, Mosby-Year Book Europe Ltd. Lynton House, 7-12. Tavistock Square, London WCH 9LB, England.
- Rasheed, M.U., Thajuddin, N., Ahamed, P., Teklemariam, Z. and Jamil, K. (2014). Antimicrobial drug resistance in strains of *Escherichia coli* isolated from food sources. *Rev. Inst. Med. Trop. Sao Paulo.* 56(4): 341-346.
- Robinson, T.P., Bu, D.P., Carrique-Mas, J., Fevre, E.M., Gilbert, M., Grace, D., Hay, S.I., Jiwakanon, J., Kakkar, M., Kariuki, S., Laxminarayan, R., Lubroth, J., Magnusson, U., Thi Ngoc, P., Van Boeckel, T.P. and Woolhouse, M.E.J. (2016). Antibiotic resistance is the quintessential One Health issue. *Trans. R. Soc. Trop. Med. Hyg.* 110(7): 377-380.
- Ross, J.I., Eady, E.A., Cove, J.H., and Cunliffe, W.J. (1998). 16S rRNA Mutation Associated with Tetracycline Resistance in a Gram-Positive Bacterium. *Antimicrob. Agents Chemother.* 42(7): 1702-1705.
- Van Boeckel, T.P., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B.T., Levin, S.A. and Laxminarayan, R. (2014). Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. *Lancet Infect. Dis.* 14(8): 742-750.
- Walsh, C.T., Fisher, S.L., Park, I.S., Prahalad, M. and Wu, Z. (1996). Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. *Chemistry & Biology.* 3: 21-28.
- Zenkin, N., Kulbachinskiy, A., Bass, I. and Nikiforov, V. (2005). Different Rifampin Sensitivities of *Escherichia coli* and *Mycobacterium tuberculosis* RNA Polymerases are not explained by the difference in the subunit Rifampin regions I and II. *Antimicrob. Agents Chemother.* 49(4): 1587-1590.

How to cite this article:

Hitesh Kumar and Sunil Maherchandani. 2018. Effects of Antibiotic Withdrawal on Multidrug Resistant *Escherichia coli*. *Int.J.Curr.Microbiol.App.Sci*. 7(10): 161-182.
doi: <https://doi.org/10.20546/ijcmas.2018.710.018>